The biology of circulating tumor cells

Oncogene

Volumn 35, Issue 10, 2016, Pages 1216-1224

  Pantel, K ^a   Speicher, M R ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITHELIAL CELL ADHESION MOLECULE; INTERSTITIAL COLLAGENASE; TRANSCRIPTOME;

BREAST METASTASIS; CANCER SURVIVAL; CIRCULATING TUMOR CELL; CIRCULATION; CYTOLOGY; DISSEMINATED CANCER; DRUG RESISTANCE; GENE MUTATION; GENOTYPE; GLIOBLASTOMA; HUMAN; METASTASIS; METASTASIS POTENTIAL; MINIMAL RESIDUAL DISEASE; NONHUMAN; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; ANIMAL; METABOLISM; MUTATION; PATHOLOGY; TUMOR EMBOLISM;

ANIMALS; HUMANS; MUTATION; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING;

EID: 84960810080     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.192     Document Type: Review

References (119)

1. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz Jr LA, Kinzler KW. Cancer genome landscapes. Science 2013; 339: 1546-1558.
2. Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet 2010; 11: 31-46.
3. Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabé RR et al. International Cancer Genome C International network of cancer genome projects. Nature 2010; 464: 993-998.
4. Cancer Genome Atlas Research N, Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519-525.
5. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C et al. Mutational landscape and significance across 12 major cancer types. Nature 2013; 502: 333-339.
6. Uhr JW, Pantel K. Controversies in clinical cancer dormancy. Proc Natl Acad Sci USA 2011; 108: 12396-12400.
7. Kreso A, O'Brien CA, van Galen P, Gan OI, Notta F, Brown AM et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 2013; 339: 543-548.
8. Speicher MR, Pantel K. Tumor signatures in the blood. Nat Biotechnol 2014; 32: 441-443.
9. Alix-Panabieres C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem 2013; 59: 110-118.
10. Alix-Panabieres C, Pantel K. Challenges in circulating tumour cell research. Nat Rev Cancer 2014; 14: 623-631.
11. Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov 2014; 4: 650-661.
12. Heitzer E, Auer M, Ulz P, Geigl JB, Speicher MR. Circulating tumor cells and DNA as liquid biopsies. Genome Med 2013; 5: 73.
13. Krebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive C. Molecular analysis of circulating tumour cells-biology and biomarkers. Nat Rev Clin Oncol 2014; 11: 129-144.
14. Yu M, Stott S, Toner M, Maheswaran S, Haber DA. Circulating tumor cells: approaches to isolation and characterization. J Cell Biol 2011; 192: 373-382.
15. Vanharanta S, Massague J. Origins of metastatic traits. Cancer Cell 2013; 24: 410-421.
16. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004; 4: 448-456.
17. Bednarz-Knoll N, Alix-Panabieres C, Pantel K. Clinical relevance and biology of circulating tumor cells. Breast Cancer Res 2011; 13: 228.
18. Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer 2009; 9: 302-312.
19. Janni W, Vogl FD, Wiedswang G, Synnestvedt M, Fehm T, Juckstock J et al. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse - a European pooled analysis. Clin Cancer Res 2011; 17: 2967-2976.
20. Hüsemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008; 13: 58-68.
21. Podsypanina K, Du YC, Jechlinger M, Beverly LJ, Hambardzumyan D, Varmus H. Seeding and propagation of untransformed mouse mammary cells in the lung. Science 2008; 321: 1841-1844.
22. Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F et al. EMT and dissemination precede pancreatic tumor formation. Cell 2012; 148: 349-361.
23. Sänger N, Effenberger KE, Riethdorf S, Van Haasteren V, Gauwerky J, Wiegratz I et al. Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ. Int J Cancer 2011; 129: 2522-2526.
24. He W, Wang H, Hartmann LC, Cheng JX, Low PS. In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry. Proc Natl Acad Sci USA 2007; 104: 11760-11765.
25. Guzvic M, Braun B, Ganzer R, Burger M, Nerlich M, Winkler S et al. Combined genome and transcriptome analysis of single disseminated cancer cells from bone marrow of prostate cancer patients reveals unexpected transcriptomes. Cancer Res 2014; 74: 7383-7394.
26. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
27. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 2011; 20: 576-590.
28. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013; 339: 580-584.
29. LeBleu VS, O'Connell JT, Gonzalez Herrera KN, Wikman H, Pantel K, Haigis MC et al. PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol 2014; 16: 992-1003 1001-1015.
30. Tarin D, Thompson EW, Newgreen DF. The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res 2005; 65: 5996-6000; discussion 6000-5991.
31. Fidler IJ. The relationship of embolic homogeneity, number, size and viability to the incidence of experimental metastasis. Eur J Cancer 1973; 9: 223-227.
32. Liotta LA, Saidel MG, Kleinerman J. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res 1976; 36: 889-894.
33. Cho EH, Wendel M, Luttgen M, Yoshioka C, Marrinucci D, Lazar D et al. Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Phys Biol 2012; 9: 016001.
34. Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 2012; 30: 525-532.
35. Ni X, Zhuo M, Su Z, Duan J, Gao Y, Wang Z et al. Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proc Natl Acad Sci USA 2013; 110: 21083-21088.
36. Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci USA 2010; 107: 18392-18397.
37. Labelle M, Hynes RO. The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discov 2012; 2: 1091-1099.
38. Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 2014; 158: 1110-1122.
39. Bailey CK, Mittal MK, Misra S, Chaudhuri G. High motility of triple-negative breast cancer cells is due to repression of plakoglobin gene by metastasis modulator protein SLUG. J Biol Chem 2012; 287: 19472-19486.
40. Holen I, Whitworth J, Nutter F, Evans A, Brown HK, Lefley DV et al. Loss of plakoglobin promotes decreased cell-cell contact, increased invasion, and breast cancer cell dissemination in vivo. Breast Cancer Res 2012; 14: R86.
41. Pantel K, Passlick B, Vogt J, Stosiek P, Angstwurm M, Seen-Hibler R et al. Reduced expression of plakoglobin indicates an unfavorable prognosis in subsets of patients with non-small-cell lung cancer. J Clin Oncol 1998; 16: 1407-1413.
42. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004; 10: 6897-6904.
43. Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 2013; 31: 539-544.
44. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007; 450: 1235-1239.
45. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004; 10: 8152-8162.
46. Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert WE, Goldbrunner R, Herms J et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat Med 2010; 16: 116-122.
47. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 2009; 20: 1223-1229.
48. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791.
49. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14: 6302-6309.
50. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-smallcell lung cancer. J Clin Oncol 2011; 29: 1556-1563.
51. Hodgkinson CL, Morrow CJ, Li Y, Metcalf RL, Rothwell DG, Trapani F et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med 2014; 20: 897-903.
52. Zhang L, Ridgway LD, Wetzel MD, Ngo J, Yin W, Kumar D et al. The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med 2013; 5: 180ra148.
53. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009; 69: 2912-2918.
54. Campos M, Prior C, Warleta F, Zudaire I, Ruiz-Mora J, Catena R et al. Phenotypic and genetic characterization of circulating tumor cells by combining immunomagnetic selection and FICTION techniques. J Histochem Cytochem 2008; 56: 667-675.
55. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008; 359: 366-377.
56. Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann EM et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and nextgeneration sequencing. Cancer Res 2013; 73: 2965-2975.
57. Mathiesen RR, Fjelldal R, Liestol K, Due EU, Geigl JB, Riethdorf S et al. Highresolution analyses of copy number changes in disseminated tumor cells of patients with breast cancer. Int J Cancer 2012; 131: E405-E415.
58. Fiegler H, Geigl JB, Langer S, Rigler D, Porter K, Unger K et al. High resolution array-CGH analysis of single cells. Nucleic Acids Res 2007; 35: e15.
59. Hou Y, Song L, Zhu P, Zhang B, Tao Y, Xu X et al. Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell 2012; 148: 873-885.
60. Zong C, Lu S, Chapman AR, Xie XS. Genome-wide detection of single-nucleotide and copy-number variations of a single human cell. Science 2012; 338: 1622-1626.
61. Navin NE. Cancer genomics: one cell at a time. Genome Biol 2014; 15: 452.
62. Van Loo P, Voet T. Single cell analysis of cancer genomes. Curr Opin Genet Dev 2014; 24: 82-91.
63. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J et al. Tumour evolution inferred by single-cell sequencing. Nature 2011; 472: 90-94.
64. Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 2014; 512: 155-160.
65. Heidary M, Auer M, Ulz P, Heitzer E, Petru E, Gasch C et al. The dynamic range of circulating tumor DNA in metastatic breast cancer. Breast Cancer Res 2014; 16: 421.
66. Lohr JG, Adalsteinsson VA, Cibulskis K, Choudhury AD, Rosenberg M, Cruz-Gordillo P et al. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol 2014; 32: 479-484.
67. Sandberg R. Entering the era of single-cell transcriptomics in biology and medicine. Nat Methods 2014; 11: 22-24.
68. Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, Deng G et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS ONE 2012; 7: e33788.
69. Seiden MV, Kantoff PW, Krithivas K, Propert K, Bryant M, Haltom E et al. Detection of circulating tumor cells in men with localized prostate cancer. J Clin Oncol 1994; 12: 2634-2639.
70. Xi L, Nicastri DG, El-Hefnawy T, Hughes SJ, Luketich JD, Godfrey TE. Optimal markers for real-time quantitative reverse transcription PCR detection of circulating tumor cells from melanoma, breast, colon, esophageal, head and neck, and lung cancers. Clin Chem 2007; 53: 1206-1215.
71. Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E et al. Inertial focusing for tumor antigen-dependent and-independent sorting of rare circulating tumor cells. Sci Transl Med 2013; 5: 179ra147.
72. Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med 2010; 2: 25ra23.
73. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014; 371: 1028-1038.
74. Yu M, Ting DT, Stott SL, Wittner BS, Ozsolak F, Paul S et al. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature 2012; 487: 510-513.
75. Ting DT, Wittner BS, Ligorio M, Vincent Jordan N, Shah AM, Miyamoto DT et al. Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. Cell Rep 2014; 8: 1905-1918.
76. Pantel K, Deneve E, Nocca D, Coffy A, Vendrell JP, Maudelonde T et al. Circulating epithelial cells in patients with benign colon diseases. Clin Chem 2012; 58: 936-940.
77. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010; 464: 999-1005.
78. Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci USA 2008; 105: 4283-4288.
79. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
80. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW et al. A geneexpression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
81. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
82. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467: 1114-1117.
83. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010; 467: 1109-1113.
84. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organspecific colonization. Nat Rev Cancer 2009; 9: 274-284.
85. Wan L, Pantel K, Kang Y. Tumor metastasis: moving new biological insights into the clinic. Nat Med 2013; 19: 1450-1464.
86. Fischer JC, Niederacher D, Topp SA, Honisch E, Schumacher S, Schmitz N et al. Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients. Proc Natl Acad Sci USA 2013; 110: 16580-16585.
87. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 563-572.
88. Gao H, Chakraborty G, Lee-Lim AP, Mo Q, Decker M, Vonica A et al. The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell 2012; 150: 764-779.
89. Lu X, Mu E, Wei Y, Riethdorf S, Yang Q, Yuan M et al. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell 2011; 20: 701-714.
90. Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 2011; 121: 1298-1312.
91. Oskarsson T, Batlle E, Massague J. Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell 2014; 14: 306-321.
92. Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L et al. Tumor self-seeding by circulating cancer cells. Cell 2009; 139: 1315-1326.
93. Valiente M, Obenauf AC, Jin X, Chen Q, Zhang XH, Lee DJ et al. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell 2014; 156: 1002-1016.
94. Chen H, Shah AS, Girgis RE, Grossman SA. Transmission of glioblastoma multiforme after bilateral lung transplantation. J Clin Oncol 2008; 26: 3284-3285.
95. Müller C, Holtschmidt J, Auer M, Heitzer E, Lamszus K, Schulte A et al. Hematogenous dissemination of glioblastoma multiforme. Sci Transl Med 2014; 6: 247ra101.
96. Fonkem E, Lun M, Wong ET. Rare phenomenon of extracranial metastasis of glioblastoma. J Clin Oncol 2011; 29: 4594-4595.
97. Seoane J, De Mattos-Arruda L. Escaping out of the brain. Cancer Discov 2014; 4: 1259-1261.
98. Mandybur TI, Liwnicz BH, Wechsler W. Disseminated (metastatic) tumors in nude mice produced by intravenous injection of cells of human and nonhuman neurogenic tumor lines. Acta Neuropathol 1984; 63: 203-209.
99. Goss PE, Chambers AF. Does tumour dormancy offer a therapeutic target? Nat Rev Cancer 2010; 10: 871-877.
100. Kang Y, Pantel K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell 2013; 23: 573-581.
101. Pantel K, Alix-Panabieres C. Bone marrow as a reservoir for disseminated tumor cells: a special source for liquid biopsy in cancer patients. Bonekey Rep 2014; 3: 584.
102. Sosa MS, Bragado P, Aguirre-Ghiso JA. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer 2014; 14: 611-622.
103. Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, Brazier H et al. The perivascular niche regulates breast tumour dormancy. Nat Cell Biol 2013; 15: 807-817.
104. Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC et al. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 2014; 345: 216-220.
105. Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science 2014; 345: 1247125.
106. Karthaus WR, Iaquinta PJ, Drost J, Gracanin A, van Boxtel R, Wongvipat J et al. Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell 2014; 159: 163-175.
107. Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 2014; 159: 176-187.
108. Alix-Panabieres C, Vendrell JP, Pelle O, Rebillard X, Riethdorf S, Muller V et al. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem 2007; 53: 537-539.
109. Alix-Panabieres C. EPISPOT assay: detection of viable DTCs/CTCs in solid tumor patients. Recent Results Cancer Res 2012; 195: 69-76.
110. Deneve E, Riethdorf S, Ramos J, Nocca D, Coffy A, Daures JP et al. Capture of viable circulating tumor cells in the liver of colorectal cancer patients. Clin Chem 2013; 59: 1384-1392.
111. Cayrefourcq L, Mazard T, Joosse S, Solassol J, Ramos J, Assenat E et al. Establishment and characterization of a cell line from human circulating colon cancer cells. Cancer Res 2015; 75: 892-901.
112. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012; 481: 506-510.
113. Almendro V, Cheng YK, Randles A, Itzkovitz S, Marusyk A, Ametller E et al. Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep 2014; 6: 514-527.
114. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011; 11: 426-437.
115. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N et al. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci Transl Med 2014; 6: 224ra224.
116. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013; 368: 1199-1209.
117. Heitzer E, Auer M, Hoffmann EM, Pichler M, Gasch C, Ulz P et al. Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int J Cancer 2013; 133: 346-356.
118. Kidess E, Jeffrey SS. Circulating tumor cells versus tumor-derived cell-free DNA: rivals or partners in cancer care in the era of single-cell analysis? Genome Med 2013; 5: 70.
119. Pantel K, Alix-Panabieres C. Real-time liquid biopsy in cancer patients: fact or fiction? Cancer Res 2013; 73: 6384-6388.